These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28049164)

  • 1. Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund.
    Torjesen I
    BMJ; 2017 Jan; 356():i6864. PubMed ID: 28049164
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.
    Palmer DH; Hussain SA; Smith AJ; Hargreaves S; Ma YT; Hull D; Johnson PJ; Ross PJ
    Br J Cancer; 2013 Aug; 109(4):888-90. PubMed ID: 23880824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NICE rules that drug used in advanced liver cancer is not cost effective for the NHS.
    Mayor S
    BMJ; 2009 Nov; 339():b4956. PubMed ID: 19933742
    [No Abstract]   [Full Text] [Related]  

  • 4. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Rognoni C; Ciani O; Sommariva S; Tarricone R
    Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of intermediate-stage hepatocellular carcinoma.
    Finn RS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
    [No Abstract]   [Full Text] [Related]  

  • 8. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of sorafenib in hepatocellular carcinoma.
    Gholam P
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.
    Petrou PK; Talias MA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):131-8. PubMed ID: 24397606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
    Zhang P; Yang Y; Wen F; He X; Tang R; Du Z; Zhou J; Zhang J; Li Q
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):853-9. PubMed ID: 25919775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
    Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
    [No Abstract]   [Full Text] [Related]  

  • 14. FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
    Zhang P; Wen F; Li Q
    Dig Liver Dis; 2016 Dec; 48(12):1492-1497. PubMed ID: 27486048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S; de Gramont A; Raymond E
    Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
    Marotta V; Colao A; Faggiano A
    Endocrine; 2015 Dec; 50(3):824-5. PubMed ID: 25754914
    [No Abstract]   [Full Text] [Related]  

  • 17. A rare primary liver tumor that responded to sorafenib.
    Seino S; Tsuchiya A; Watanabe M
    Gastroenterology; 2014 Dec; 147(6):1226-7. PubMed ID: 25450081
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
    de Stefano G; Iodice V; Farella N
    J Gastrointest Cancer; 2015 Dec; 46(4):430-3. PubMed ID: 25894635
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of restricting access to high-cost medications for hepatocellular carcinoma.
    Ma YT; Palmer DH
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):465-73. PubMed ID: 22971033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
    Westgeest HM; van Erp NP; Honeywell RJ; Hoekstra R; Peters GJ; Verheul HM
    J Clin Oncol; 2013 Feb; 31(6):e83-6. PubMed ID: 23182994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.